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The human gut microbiome is considered an organ in its entirety and has been the
subject of extensive research due to its role in physiology, metabolism, digestion, and
immune regulation. Disequilibria of the normal microbiome have been associated with the
development of several gastrointestinal diseases, but the exact underlying interactions
are not well understood. Conventional in vivo and in vitro modelling systems fail to faith-
fully recapitulate the complexity of the human host–gut microbiome, emphasising the
requirement for novel systems that provide a platform to study human host–gut micro-
biome interactions with a more holistic representation of the human in vivo microenviron-
ment. In this review, we outline the progression and applications of new and old
modelling systems with particular focus on their ability to model and to study host–micro-
biome cross-talk.
Introduction
The development of novel prognostic tools and effective therapeutic strategies relies upon a profound
understanding of the molecular mechanisms involved in health and disease, including inﬂuences
from the microbiome [1,2]. For example, the microbiome that inhabits the human gut is integral in
regulating normal gut homeostasis. Such physiological functions include aiding digestion, producing
metabolites from undigested ﬁbre, regulating drug metabolism, adapting immune responses, and
protecting the host from pathogens and infections [3–5]. The realisation that commensal and
pathogenic bacteria play a role in dysbiosis, disease development, and chronic disorders [3–5] places
an emphasis on gaining a deeper understanding of the underlying mechanisms involved in physio-
logical and pathophysiological host–microbiome cross-talk. The complexity of a holistic understanding
of these cause-and-effect relationships in humans makes human studies complicated and somewhat
limited, most notably because of the challenges in accessing the human gut, making disease-modelling
essential. Preclinical animal models and in vitro 2D cell culture studies have provided extensive
insights into the physiological and pathophysiological processes that underpin disease. However,
as they do not faithfully represent the human body, they are not suitable models to evaluate
all research questions nor model drug efﬁcacy. Moreover, the high number of therapeutic compounds
that fail to translate in clinical trials [6,7] highlights the need and importance for models that
are more physiologically relevant to the human body, in order to personalise treatments and
better predict patient outcomes. In this review, we discuss the advantages and disadvantages
of conventional modelling systems. Furthermore, we review the advantages and contributions
of 3D organoid culture and systems such as organ-on-a-chip that better recapitulate the in vivo
human body and provide a better understanding of cell–cell interactions and the host–gut microbiome
cross-talk that occurs in health and disease. The advantages and disadvantages of the systems
discussed in this review are outlined in Table 1. Figure 1 provides schematic representation of these
systems.
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Table 1. Advantages and disadvantages of current culturing techniques with respect to host–microbiome
interaction Part 1 of 3
Type of assay Advantages Disadvantages
2D ethos • Inexpensive, easy-to-use, data generated
quickly [9,10].
• Retain many genetic, epigenetic, and gene
expression features of human cancer [9,10].
• Established from metastatic tumours,
restricting their use in cancer progression
studies and early drug interventions [149].
• Not an accurate representation of the
in vivo 3D microenvironment [3,11].
• Drug doses that are effective in 2D culture
often result in poor efficacy when scaled in
to humans [10-13].
• 2D culture exerts selection pressures on
cells that alter morphology and gene
expression [10].
Transwell • Easily implemented, low-cost assay [145].
• High throughput [145].
• Can be used to compare metastatic potential of
cells [145].
• Provides thorough analysis of cells ability to
migrate and sense a chemo-attractant [145].
• Can be used to investigate cell invasion [146].
• Low physiological relevance [79].
• Migration and invasion assays can result in
conflicting data [82].
• Unstirred water layer may decrease the
permeability rate of lipid soluble
molecules [82].
• Cells are grown in a static media, and there
is no shear stress forced on the cells [147].
Organoids • Near-physiological model for epithelial tissue
containing heterogeneous cell populations —
maintaining integrity of the in vivo structure [49].
• Enable analysis of cell–cell and cell–matrix
interactions, while maintaining mechanical
properties, gene expression, and metabolic
profiles [148].
• Ex vivo culture bridges gap between cell culture
and animal modelling [149].
• Can microinject microbes into the lumen of
organoids to study host–pathogen
interactions [63].
• Organoid/enteroids can be grown in 2D
monolayers on Transwell inserts such that
microbes can be exposed to the apical cell
surface simultaneously with immune cells at the
basolateral surface, more representative of the
in vivo human microenvironment, and permits
human host–pathogen studies [42,75–77].
• Reductionist approach — epithelial cells grow
without its native microenvironment [49].
• Wrong side of epithelium exposed to
compounds/microbiome when added in
the media [43].
SynVivo®
(SynTumour)
• Realistic vasculature morphology and
physiology with diffusion transport [81].
• SynVivo’s inflammatory model has been
successfully validated against in vivo
studies [85,86].
• Excellent correlation with rolling velocities,
adhesion patterns, and migratory
processes [85,86].
• A SynVivo produced chip can partly mimic the
in vivo blood–tumour barrier [82].
• Still cannot be used without conjunction of
animal testing [150].
• Hard-to-remove bubbles can form —
rendering the chip unusable [81].
• Not yet applicable to studying microbiome
interaction.
Tissue slices • Has the ability to assess the role of the tumour
microenvironment on tumour growth and
survival [92].
• Freshly resected tissue slices are viable for at
least 24 h [92].
• Tissues start to deteriorate after 3 weeks in
culture (tissue-dependent) [152].
• Donor-to-donor variability [152].
• Difficulty in monitoring cells beyond the
depth of confocal microscopy (unless cells
are isolated for analysis) [152].
Continued
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Table 1. Advantages and disadvantages of current culturing techniques with respect to host–microbiome
interaction Part 2 of 3
Type of assay Advantages Disadvantages
• Contains a higher level of biological
organisation, and has cell–cell interaction, which
may better reflect the response of the target
organ [151].
• Can be used to represent all regions within a
tissue [91,92].
• Effect of microbiome and pathogenic bacteria
on epithelial integrity, permeability, and
contractility can be examined when tissue slices
are used in conjunction with Ussing chambers
[95,98,101].
• The system does not reflect the effects of
in vivo systemic factors [152].
• Further work is required to maintain
anaerobic microbes in intestine [94].
Organ/tissue
baths
• Versatile, simple, and reproducible assay that is
suitable for all organ sizes [103,104].
• Ability to measure concentration-dependent
changes to isometric contractions [103].
• Experiment is in real time — can rapidly make
conclusions and troubleshoot [103].
• 3R’s — multiple tissues can be prepared from
one animal [103].
• Scope to study probiotic and pathogenic
microbes ex vivo [107].
• Organs/tissues may experience different
degrees of damage during surgical
removal [103].
• Organs/tissues may also have different
viability lengths [103].
• Responsiveness of tissues may alter —
time controls may be necessary [103].
• New tissue required for each experiment
[105,106] hindering studies that follow
genetic backgrounds.
Organ-on-a-chip • Enables research into physiological and
pathophysiological responses of tissues, with
interaction from microbes [153,154].
• Can be exploited to complement animal
studies and even bypass animal modelling in
the future [153].
• Accurately predict pharmacological effects in
patients [153,154].
• Raw materials used are relatively cheap [153].
• Cheap, versatile, precise, and reliable system [114].
• Microengineering complexities [155],
cleanrooms, and pumps can be
costly [153].
• Surface area and roughness of chip and
formation of bubbles can affect capillary
forces and flow rate of the microfluid,
which can damage cells [154].
• Matrix degrades when culturing time
increases, affecting cell functionality [153].
• Cannot reflect chronic diseases, adaptive
immune responses, or mirror complicated
behaviours of the endocrine, skeletal, or
nervous systems [156].
• Human testing is still necessary [155,156].
Quasi-Vivo®
(Kirkstall)
• Provides a flexible and easy system that enables
long-term co-culture of multiple cell types and
improves cell viability [157].
• Has the ability to apply high flow rates and
create high nutrient turnover to cells without
imposing high shear stress or turbulent
flow [158].
• Enables microwell protocols to be transferred
directly to the bioreactor modules without the
need to redesign cell culture [130].
• Control of oxygen tension to visually represent
conditions at the surface and within
tumours [130].
• Currently has a limited ability to model all
tissue types [130].
• The allometric aspects of dosage are
unknown [130].
• Not applicable to microbiome studies.
HuMiX module • Can simultaneously establish aerobic and
anaerobic conditions and measure oxygen
levels in real time [133].
• Effects of individual and combinations of
bacteria on host physiology are possible [134].
• Cell types cannot fully represent the cellular
makeup of the entire intestinal tract
[133,134].
Continued
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2D culture and in vivo animal models to study human
disease
Human cell lines have had a fundamental role in determining the importance of pathways involved in disease
and have been a good platform for screening and characterising drug therapeutics [8]. Cell lines retain many
genetic, epigenetic and gene expression features of human disease [9,10]. However, they fail to represent the in
vivo 3D microenvironment, induce cell differentiation [11,12], perform tissue-speciﬁc functions [11,13,14], and
do not represent the natural cell heterogeneity that compose primary tumours [9]. In addition, it is often found
that drug doses that are effective in 2D culture result in poor efﬁcacy when scaled to humans [6,15–17]. Many
of these limitations are addressed by genetically engineered mouse models (GEMMs). GEMMs have been an
extremely useful tool for studying early and chronic stages of human disease [8], as they share similarities in
anatomy, physiology, and genetics [18–22]. However, their use for investigating host–microbiome interactions
is limited by the differences in lifespan, variations in diet, and microbiome populations [23]. The inability of
these systems to study the cause-and-effect relationships of the host–microbiome interactions in a meaningful
way is driving the development of systems to overcome this issue.
Table 1. Advantages and disadvantages of current culturing techniques with respect to host–microbiome
interaction Part 3 of 3
Type of assay Advantages Disadvantages
• Can co-culture individual cell lines that are in
close proximity to other cell types, yet can be
exposed to independent conditions — great for
understanding microecology of gut [134].
• Ecology of communities can be manipulated,
meaning transition states can be studied —
potential for identification of early biomarkers in
disease linked with dysbiosis [134].
Figure 1. Current cell modelling systems and their potential to model host-microbiome cross-talk.
Schematic representation of current cell culturing techniques available and their ability to model host–microbiome interactions.
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Cell culturing systems for studying the human microbiome
The gastrointestinal (GI) tract contains a ﬂora of commensal bacteria, known as the microbiome [24]. The
living gut microbiome has been of increasing interest in recent years, as its role in the regulation of the
immune system, local barrier functions, homeostasis, and tissue regeneration and also in the development of
certain diseases (e.g. Crohn’s disease, inﬂammatory bowel disease, and coeliac disease) are not fully understood
[3,5,25]. Additionally, it is known that the gut microbiome can inﬂuence drug absorption and metabolism
[3,26]. Thus, it is paramount that host–gut microbiome interactions are elucidated.
Advancements in techniques for culturing cells have been critical for identifying and understanding cell
involvement in disease initiation. In vitro sphere-forming assays were among the ﬁrst techniques adopted to
study these interactions. The sphere-forming assays were initially developed to study neural stem cells [27] and
were later developed to culture mammary stem cells [28]. In these cultures, cells aggregate together to form 3D
spheroid structures, which can then be utilised to determine stem cell behaviour of both human and animal
cell populations [29,30]. Typically, the study of human GI disease has relied upon culturing intestinal epithelial
cells in static well plate assays. For example, Transwell culture has been used to grow a polarised monolayer of
human cell lines [31] on a nanoporous insert [3]. Microbial cells, probiotic [32–35] or pathogenic [36–39], can
then be added to the apical cell surface. To gain further insights, immune cells can be simultaneously added to
the basolateral side of the monolayer culture [31,40–42]. Transwell culture is limited however, as cultured epi-
thelial cells do not produce functional specialised cell types [12,43]. Consequently, a substantial amount of
research has focused on the development of a 3D culturing technique, initially using individual murine intes-
tinal stem cells [44,45] and also patient-derived tissues and human stem cells [46–48] that grow into self-
renewing organoids that encompass the structure, and all cell types of the in vivo intestinal crypt, providing a
more human-relevant model.
The progression from 2D to 3D organoid culture
Long-term organoid culturing has been a major breakthrough in research and is now an extensively used tool
for studying both basic and clinical biology [49–51]. Advancement in technology has enabled culturing of the
stomach [52–54], pancreas [55–57], liver [58], prostate [59,60], oesophagus [46,61], gall bladder [62,63], and
taste buds [64]. Additionally, CRISPR-Cas9 technology has been exploited to induce gene editing in intestinal
organoids that mimics the sequential loss and gain of functions of genes involved in human colorectal cancer
[65], which, after in orthotopic engraftment, could metastasise to the liver [66,67]. Thus, organoid models can
be used to study advanced aspects of cancer development in a more complexed in vivo scenario. Organoid
culture has been exploited to investigate host–gut microbiome interactions by microinjection of microbes to the
lumen of organoids (apical surface, as this mimics aspects of microbial infection in vivo) or basally by the add-
ition of microbes to the media [63]. The potential of organoids as a model for studying host–microbial interac-
tions has been demonstrated using human gastric organoids and the pathogenic microbe, Helicobacter pylori
[54,68,69], that is known to cause infection, ulceration, and gastric cancer in humans [70]. Apical infection of
gastric organoids with H. pylori recapitulates known hallmarks of infection, including a marked increase in
mucus-secreting cell expression, induction of cytokine production via up-regulation of NF-κB (known to
induce gastritis), and production of the H. pylori virulence factor CagA (cytotoxin-associated gene A), which is
associated with motogenesis and tumour progression [71,72]. Other studies have been able to efﬁciently infect
human-derived organoids in a similar manner with a range of known pathogens, including Salmonella typhi-
murium [63], Clostridium difﬁcile [73,74], and rotaviruses [75]. Thus, these studies present a valuable near-
physiological modelling system in which to begin deciphering the complex interactions between host epithelium
and infectious agents. Additionally, several recent studies have improved the human relevance of Transwell cul-
tures. For example, Transwells have been adapted to grow human small intestinal and colonic organoids in
monolayers on Transwell membranes that support microbial (Escherichia coli [42,76,77] and norovirus [78])
adherence at the cell surface, as seen in vivo. The above studies have provided an informative platform that can
be exploited to use patient-derived tissues to study donor-speciﬁc disease progression, host responses to enteric
pathogens, and provide a platform to develop personalised treatments.
However, like any other system, organoid culture has its limitations. In instances where microbes are added
to culture medium, microbial overgrowth often occurs, which can damage the epithelium and can hinder long-
term co-culture, this is also the case with co-culturing human cell lines with microbes using Transwells [3,43]
and, thus, should be avoided where possible. It is not possible to exert peristalsis-like motions (which is
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required in vivo to sustain intestinal differentiation and conﬁne microbial overgrowth [14]) to the cells cultured
in Transwell or organoid culture. And the reductionist approach of organoid culture limits the full potential of
this method as epithelial cells grow without their native microenvironment, and the true contributions from
the stroma, extracellular matrix (ECM), oxygen, vasculature, immune system, and the microbiome cannot be
truly assessed [49,79]. This ultimately impedes the understanding of the precise molecular mechanisms
involved in transition from healthy to disease states and limits the potential efﬁcacy of interventions when
translated to clinic.
It is evident that models, which reﬂect the holistic environment, are crucial to better predict patient out-
comes to therapy, understand the mechanisms that underpin disease and the role environmental factors, such
as diet, have on physiology and pathophysiology [12]. The integration of microﬂuidics with living biological
systems has paved the way for new techniques such as the exciting ‘organ-on-a-chip’ concepts, which aims at
developing advanced in vitro models that replicate the key features of human tissues and organs [80]. The cul-
turing methods outlined below are discussed in increasing order of their ability to represent the in vivo environ-
ment and its suitability to study host–microbe interactions.
SynVivo®
SynVivo microﬂuidic models have been developed to study human tissue microvasculature, cell–cell, and cell–
drug interactions in a 3D setting, in the context of in vivo-relevant ﬂow and pressures [81]. Currently, SynVivo
models have four independent assays that represent the blood–brain barrier [82–84], cancer [85], inﬂammation,
[86,87] and toxicology. SynVivo devices utilise polydimethylsiloxane (PDMS) chambers that comprise a micro-
ﬂuidic map of vasculature with spaces that can be lined with ECM. For example, endothelial cells can be cul-
tured on ﬁbronectin-coated channels and activated using cytokines. Endothelial cell interactions with white
blood cells can then be assessed in real time by the injection of cells into the system [81]. Synthetic network
assays can also recapitulate in vivo leaky vasculature associated with tumourigenesis and thus can be utilised to
study both basic and applied research [81]. To date, SynVivo chips have not yet been developed to study micro-
bial interactions; however, its ability to recreate a realistic vasculature network surrounding a tissue will make a
profound advancement in modelling in vivo 3D environments.
Tissue slices
Precision-cut tissue slices (PCTS) are a useful tool for metabolic, pharmacology, and toxicological studies [88–
90]. Predominately used to model solid organs (e.g. liver and kidney) and agarose-embedded non-solid organs
such as the intestine [91,92], uniform tissue slices are cut and incubated in media in 6- or 12-well plates and
exposed to atmospheric conditions [92]. PCTS are believed to have advantages over organoids and
organ-on-a-chip (discussed later), as they represent all regions of the tissue [91]. It has been reported that
murine intestine is maintained for 6 days in the presence of normal neuronal, muscular, and mucosal struc-
tures with contractibility functions and some immune responses, therefore, representing a more holistic intes-
tinal organ [93]. Additionally, in the absence of antibiotic media, some aerobic commensal microbes can be
maintained [93]. Although this system holds great promise to study holistically the complex mechanisms that
underpin healthy gut functions and disease in a 3D physiologically relevant environment, further work is
required to maintain anaerobic microbes that are predominately found within the intestinal environment [94].
In addition to maintaining tissue slices in media, epithelial integrity, neural activity, ion/nutrient/drug transport
[95–97], and the effect of microbiota and pathogenic bacteria on these processes [98–101] can be examined
using analytical tools, such as the Ussing chamber. As this tool compartmentalises the apical and basolateral
surfaces of the tissue, each surface can be exposed to independent physiological solutions [95], representative of
the in vivo microenvironment. The potential of the Ussing chamber to investigate host–pathogen interactions
was highlighted when co-culture of human cell lines with the infection-causing bacteria, C. difﬁcile, extensively
impaired epithelial barrier function and elicited cytotoxic immune responses which contributes to C. difﬁcile-
mediated pathogenesis [101]. One limitation of the Ussing chamber, however, is that intestinal tissue viability
is often limited to 3 h which limits long-term optimal tissue function studies [102].
Organ baths
Organ bath assays play important roles in evaluating concentration–response relationships in a variety of
tissues, predominately contractile organs. The primary advantage of organ baths is that live tissue is cultured
that continues to function as a whole unit with respect to contractions visualised in vivo. By retaining these
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physiological functions, pharmaceutical interactions can be examined to predict in vivo responses [103,104].
However, because of using relatively large samples, the core of the suspended tissue strips can often become
hypoxic, which can hinder contractile readouts [104]. Another caveat with organ baths is the requirement of
fresh tissue for each experiment [105,106]. This prevents analysis from a single donor or genetic background,
which is achievable through 3D organoid culture. However, organ baths have been used to show that E. coli sti-
mulates the contractility of human colonic smooth muscle cells [107]. Thus, there is scope for advancing organ
bath techniques to study probiotic and pathogenic microbes ex vivo.
Organ-on-a-chip
To mimic key aspects of living organs, such as the multicellular structures, cell–cell and tissue–tissue interac-
tions, and the native microenvironment, organ-on-a-chip systems have been developed to incorporate micro-
ﬂuidic and microengineering technology [7,108]. The beneﬁt of developing such systems is that it provides a
platform to study the complex physiological and pathophysiological responses of tissues at an organ level, to
provide patients with quicker access to new medication. For example, microﬂuidics can be utilised to mimic
blood and nutrient ﬂow and maintain mucus transition in lung epithelia [108,109]. In addition, this system can
be exploited to complement animal studies and also more accurately predict pharmacological effects in patients
and, in the future, could be used to bypass the use of animal testing completely [110]. Organ-on-a-chip has
been developed for several organs, including the lung [111,112], heart [113,114], liver [115], neuron [116],
kidney [117,118], gut [14,43,119], blood vessel [120,121], tumour-on-a-chip [122], bone marrow-on-a-chip
[123], liver-tumour-bone marrow-on-a-chip [124], and liver-skin-intestine-kidney-on-a-chip [125]. These
systems can be extended to disease modelling, pharmaceutical analysis, drug development strategies
[6,118,122], and understanding host–microbe interactions [14,111,122]. For the purpose of this review, we will
discuss the use of organ-on-a-chip to study intestinal dynamics with particular focus on the gut microbiome.
The potential of these systems to accurately model drug uptake and metabolism in the human body has
recently been shown in the context of products produced by the microbiome. Vernetti et al. (2017) demon-
strated that a liver-intestine-kidney-on-a-chip system integrated with an intact blood–brain barrier/neurovascu-
lar unit sufﬁciently modelled in vivo trimethylamine (a by-product of the microbiome) metabolism.
Speciﬁcally, trimethylamine, microinjected into intestinal organoids, was found in the basolateral media and
was subsequently metabolised to trimethylamine N-oxide by the liver module and then secreted into the lumen
of the kidney module, which occurs in vivo. The study also revealed a novel ﬁnding that trimethylamine
N-oxide crosses the blood–brain barrier [126], emphasising the potential of such systems to further our under-
standing of human physiology.
Progression to gut-on-a-chip assays
The applications of gut-on-a-chip systems are still at the early stages of development [80]; however, they hold
great promise for studying the interactions between host and microbiome. Initial studies involved culturing a
monolayer of human epithelial Caco-2 cells inside a microﬂuidic device [127]. Although this microchip pro-
vided a vascular ﬂow over the cells, the ability of Caco-2 cells to reach conﬂuence was hindered. This was likely
caused from inherent faults within the system that did not allow large volumes of medium, and thus nutrients,
to be administered at a time, and resulted in cellular damage from dead cell debris, air bubbles, and the inabil-
ity to maintain a stable medium ﬂow [127]. These problems were circumvented by identifying optimal micro-
channel dimensions and appropriate Caco-2 cell density, which provided sufﬁcient nutrients and reduced shear
pressures that ultimately promoted Caco-2 cellular growth and normal barrier function [127]. This study high-
lights the importance of chip scaling, and this should be taken into consideration when developing novel
microﬂuidic devices in the future. More advanced microﬂuidic models have been subsequently developed,
based on the culture of Caco-2 cells under physiologically relevant conditions, including peristalsis-like
motions, intraluminal ﬂuid ﬂow, the use of 3D scaffolds, and support the growth of the naturally occurring
microbiome without diminishing cell viability [43]. These earliest models of gut-on-a-chip were adapted from
the advancements in lung-on-a-chip that enabled microﬂuidic systems to effectively model the cyclic breathing
motions of the human lung [111]. In 2012, a biomimetic human-gut-on-a-chip microdevice was developed
that consisted of two closely apposed microﬂuidic channels made from a self-adhesive elastomer, PDMS (that
is highly permeable to oxygen), creating a luminal and capillary channel [43]. Between the channels was a thin
elastic porous membrane coated with an ECM. A layer of Caco-2 cells was cultured on top of the ECM.
Culture medium was allowed to ﬂow through both channels to mimic in vivo ﬂuid ﬂow and shear stress.
© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and the Royal Society of Biology and distributed under the Creative Commons
Attribution License 4.0 (CC BY-NC-ND).
391
Emerging Topics in Life Sciences (2017) 1 385–400
https://doi.org/10.1042/ETLS20170047
Peristaltic-like deformations were instigated by cyclic suction patterns to stretch and relax the porous mem-
brane [43]. The group reported that this human-gut-on-a-chip system allowed intestinal epithelial cells to
polarise, form 3D structures that closely resembled physical and functional features of human intestine and
created a high-integrity barrier against small molecules which was not achieved when cells were cultured using
Transwell models [43]. Additionally, this system allows the study of physiological gut functions in the presence
of relevant cues and interactions with the microﬂora. Caco-2 cells have been effectively co-cultured with a nat-
urally occurring intestinal microbe, Lactobacillus rhamnosus GG (LGG), at the luminal surface which improved
intestinal barrier function [43], which has been previously reported with probiotic bacteria strains in humans
[128]. Moreover, differentiated intestinal epithelium supported the growth of naturally occurring microbiota for
more than 2 weeks, which is in contrast with Transwell and organoid cultures where cell viability is often lost
within a few hours [12,14,43]. Taken together, these studies provide support for the use of gut-on-a-chip as a
tool for studying the mechanisms involved in intestinal function and the involvement of the normal gut micro-
biome. This system also has the potential to be exploited to study the development of disease in a more
human-relevant holistic environment, become a novel platform for drug development, and better predict
responses to therapy in clinical trials.
The potential of gut-on-a-chip was proved in a proof-of-principal study in 2016 when Kim et al. studied the
contribution of the microbiome to gut pathophysiology. Speciﬁcally, Caco-2 cells were co-cultured, with eight
living human commensal microbes that have previously been used in clinical trials of chronic inﬂammatory
bowel diseases [129]. Caco-2 cells displayed distinct gene expression proﬁles and phenotypes when cultured in
the presence of commensal microbes, which closely resembled the normal human ileum. Next, the group inves-
tigated whether gut-on-a-chip was sufﬁcient to model human intestinal inﬂammation, and what contribution
the gut microbiome played. Culturing Caco-2 cells with immune cells and non-pathogenic bacteria, to induce
pro-inﬂammatory cytokines, resulted in injury to the villus structure and impaired barrier function. By inde-
pendently controlling the addition of each cytokine to the system, the authors were able to elucidate that only
in the presence of interleukin-8 were the cytokines able to induce disease-promoting effects, which is not easy
to model using GEMMs. Furthermore, the extent of villus injury and compromised barrier function was
reduced and delayed by the addition of commensal probiotic microbes within the chip. Subsequently, antibiotic
therapies that are commonly used in clinic to treat intestinal inﬂammatory disease were added to protect the
epithelial cells from damage [14]. This provides direct evidence that gut-on-a-chip is efﬁcient in mimicking the
suppression of injury responses from bacteria and the immune system that are observed clinically [14]. More
importantly, the gut-on-a-chip assay provides a robust platform to identify the individual and combinational
effects of immune cells, commensal and pathogenic microbes, and epithelia and endothelial cells in a system
that closely resembles the in vivo environment. Although still not foolproof, this system enables the study of
intestinal physiology to identify mechanisms involved in gut pathophysiology and could be used to ﬁnd novel
therapeutics in a patient-speciﬁc manner in the future.
Quasi-Vivo® (Kirkstall)
Kirkstall have designed a system based on organ-on-a-chip models to produce a ‘system-on-a-plate’ array,
named Quasi-Vivo [130]. Quasi-Vivo technology aims at producing a down-scaled system of the human body
(through the use of allometrics, [131,132]), such that in vivo biochemical and physical stimuli, metabolic, volu-
metric and exchange rate relationships are retained in vitro [130]. Advantages of Quasi-Vivo over
organ-on-a-chip devices include limited cellular damage from high wall shear stresses [130,133] and the inher-
ent issue with bubble formation, which occurs in microﬂuidic systems, is overcome due to their intelligent
design features and size [130]. Preliminary ﬁndings from Kirkstall show that E. coli is viable within the
Quasi-Vivo system and, thus, has scope for future microbial analysis.
HuMix module
The HuMiX, human–microbial cross-talk module, composes three microﬂuidic chambers that are parallel to
one another and separated by semipermeable membranes. The alignment of these chambers provides a micro-
bial, epithelial, and perfusion chamber. The speciﬁc outlets and inlets of each chamber allow for the inoculation
of cell lines and, through the perfusion of cell growth media, can precisely control the physiochemical
conditions each chamber receives [24,134,135]. This set-up builds on previous systems such that it (1) has the
ability to simultaneously establish aerobic and anaerobic conditions and (2) can monitor oxygen levels in real
time [134].
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Several proof-of-concept studies have highlighted the potential HuMiX to enhance our understanding of
host–microbe cross-talk [134,135]. Speciﬁcally, Eain et al. report that HuMiX was sufﬁcient to co-culture
Caco-2 cells and microbial cells (LGG and Bacteroides caccae) under conditions that represented the in vivo
human GI tract, i.e. the maintenance of oxygen gradients either side of the epithelium. The arterial blood
supply was mimicked by the addition of an oxygen-rich media in the perfusion chamber, which provided epi-
thelial cells with oxygen from the basal surface. In doing so, the epithelium could grow in a shear-free environ-
ment, while anaerobes were present [135]. Additionally, the group were able to co-culture immune cells via the
perfusion chamber and are now focusing on developing a system, Immuno-HuMiX, to study the interactions
between the immune system and the intestinal microbiota in the human gut. However, the authors note that
despite the success in co-culture of human and microbial cells and the potential to extend this system to study
diet, drug screening, discovery, and delivery, these cell types cannot fully represent the complex cellular
makeup of the entire intestinal tract [134,135].
Bringing cell culture techniques closer to in vivo: future
directions
There is an abundance of unknown information with regard to the complexity of the gut microbiome and its
effect on the human host, which precludes the development of novel therapeutics for disease states. Recently,
signiﬁcant advancements in the scientiﬁc ﬁeld have attempted to unravel these host–gut microbiome interac-
tions. Although the reductionist approach of previous conventional modelling systems, such as static 2D and
3D cell culture, has improved our understanding of how the gut environment is relevant to both human physi-
ology and pathophysiology, advancements in technology have paved the way to microﬂuidic-based devices that
provide a more accurate representation of the in vivo microenvironment.
Microﬂuidic platforms, such as organ-on-a-chip, HuMiX, and other devices, have signiﬁcant potential in
advancing diagnostic, pharmaceutical, and nutritional industries with respect to earlier diagnosis, expedition of
drug development, and understanding the mechanisms that underpin dietary involvement in health and
disease. As these systems permit 3D co-culture of epithelial cells with underlying endothelium, immune cells,
and microbes with the inﬂuence of ﬂow and shear effects, they will be fundamental for further improving our
understanding of the host–microbiome interactions holistically. Having said that, there are many challenges
microﬂuidic technology still face today which require tweaking to better recapitulate the in vivo host–micro-
biome environment. Firstly, most systems heavily rely on the use of Caco-2 cells as a model of human intestinal
epithelium. While this cell line has been crucial in expanding our knowledge, Caco-2 cells were originally from
a human colorectal adenocarcinoma [7,24] and thus may have attributes that distinguish them from the
normal gut epithelium and any cross-talk between the host–gut microbiome may not be a true representation
of the native intestine. Speciﬁc issues of using Caco-2 cells to model gut epithelium are (1) Caco-2 cells, a
colon cancer-derived cell line, especially in the context of gut-on-a-chip assays, are used to study small intes-
tinal villus formation [12,14,43]. It is necessary to point out that the human colonic epithelium is not com-
posed of villi [136] and that cancer cells can behave differently from normal epithelial cells. (2) Only loose
observations can be made about gut physiology when using Caco-2 cells, as it is not clear which section of the
intestine, i.e. duodenum, ileum, jejunum or colon, is being modelled. It is important to know exactly which
region of the intestine is being modelled such that is mimics the architecture, cellular makeup and immune
responses that differs throughout the intestine. For example, the small intestine tends to be more acidic and
contains a single mucosal layer, whereas the colon consists of a protective thick double-layered mucus [137]
that harbours a higher bacterial density than the small intestine [136]. Therefore, without knowing which
section of intestine is being modelled, informed conclusions cannot be made. And (3) interactions between the
host and microbes that primarily inhabit the human colon are analysed in the context of epithelial villus forma-
tion and barrier integrity. Again, this is not a true representation of human gut physiology and thus emphasises
that Caco-2 studies should be limited when evaluating gut physiology. The progression in generating primary
epithelium and organoids from stem cells holds great promise for advancing these techniques to recreate the
cellular makeup and environmental conditions prevalent in the human gut, especially in light of the available
organoid monolayer Transwell culturing methods that utilises donor-speciﬁc tissue and enables co-culture with
microbes [42,76,77] and which has the potential to be translated to organ-on-a-chip and HuMiX modelling
systems. Secondly, most microﬂuidic devices have been sufﬁcient only in culturing aerobic microbes, which
does not reﬂect the anaerobic nature of the intestinal lumen [24,94]. The development of the state-of-the-art
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HuMiX system has provided a platform to culture aerobic-dependent epithelium in the presence of anaerobic
microbes, but further reﬁnement of this system is required to decipher the complex interactions between the
holistic gut environment (stroma, immune system, diet, microbiome, and metabolome) and the roles they play
in maintaining intestinal physiology and initiating and preventing intestinal diseases. The third challenge is a
technical issue. The material, PDMS, which is currently used to generate organ-on-a-chip microﬂuidic cham-
bers does not faithfully represent the physicochemical properties of the ECM that occur in vivo, and can often
preclude drug studies as small hydrophobic molecules are absorbed by the material [138,139]. In addition,
PDMS poses challenges for large-scale reproduction of microﬂuidic chambers. However, studies have been per-
formed to identify suitable alternative materials or surface coating techniques to combat this issue [140–142].
The challenge for the future is to develop a human-on-a-chip system [143,144], through the amalgamation
of the technologies described herein, in which several chambers can be interconnected to represent all aspects
of the human body (Figure 2), including factors such as the blood–brain barrier, aerobic–anaerobic nature of
the gut epithelium, and microbiome and disease states, i.e. tumours, to functionally mimic and study the
complex interactions between the circulatory, endocrine, digestive, immune, lymphatic, nervous, respiratory,
and urinary systems. Moreover, such a system would provide a holistic scope to investigate pathophysiological
conditions through subtle manipulations within chambers and will also provide a basis to systemically assess
drug interventions in the future.
Figure 2. A proposed microﬂuidic chip to model host–microbiome cross-talk.
An amalgamation of SynVivo, organ-on-a-chip, and HuMiX culturing systems has the potential to model the host–microbiome
interactions within the entire human body, in the presence of ﬂow and shear stresses (representative of a circulatory system).
© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and the Royal Society of Biology and distributed under the Creative Commons
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Summary
• Understanding, holistically, the mechanisms that underpin human physiology and pathophysi-
ology are hindered due to the difﬁculty in accessing organs, and a paucity of information on
the interactions between the host and microbiome.
• Conventional modelling systems such as 2D cell culture and Transwells fail to faithfully repre-
sent the in vivo human environment, especially in the context of studying host−microbiome
cross-talk. Emphasising a need for novel modelling systems that better recapitulate the
human body.
• Technological advancements involving microﬂuidic techniques has paved the way for exciting
organ-on-a-chip based culturing methods.
• Novel in vitro and ex vivo culturing techniques such as patient-derived organoid culture,
SynVivo®, Quasi-Vivo®, organ-on-a-chip and HuMiX systems, are beginning to provide more
clinically relevant platforms in which to better model and study human host-microbiome
interactions.
Abbreviations
CagA, cytotoxin-associated gene A; CRISPR-Cas9, clusters of regularly interspaced short palindromic repeats-
CRISPR associated protein 9; ECM, extracellular matrix; GEMMs, genetically engineered mouse models; GI,
gastrointestinal; LGG, Lactobacillus rhamnosus GG; NF-κB, nuclear factor kappa-light-chain-enhancer of
activated B cells; PCTS, precision-cut tissue sections; PDMS, polydimethylsiloxane.
Author Contribution
S.M. and S.E. designed and wrote the manuscript. L.P. provided guidance, editing, and ﬁnal approval of
manuscript.
Funding
S.M. is supported by a philanthropic donation from the Mr Lyndon and Mrs Shirley Ann Wood from the
Moorhouse Group Ltd [grant number 512990]. L.P. is supported by a Fellowship from the European Cancer
Stem Cell Research Institute, Cardiff University, School of Biosciences [grant number AC1970LP01].
Competing Interests
The Authors declare that there are no competing interests associated with the manuscript information.
References
1 Yissachar, N., Zhou, Y., Ung, L., Lai, N.Y., Mohan, J.F., Ehrlicher, A. et al. (2017) An intestinal organ culture system uncovers a role for the nervous
system in microbe-immune crosstalk. Cell 168, 1135–1148.e12 https://doi.org/10.1016/j.cell.2017.02.009
2 Pﬂughoeft, K.J. and Versalovic, J. (2011) Human microbiome in health and disease. Ann. Rev. Pathol. 7, 99–122 https://doi.org/10.1146/
annurev-pathol-011811-132421
3 Park, G.-S., Park, M.H., Shin, W., Zhao, C., Sheikh, S., Oh, S.J. et al. (2017) Emulating host-microbiome ecosystem of human gastrointestinal tract
in vitro. Stem Cell Rev. Rep. 13, 321–334 https://doi.org/10.1007/s12015-017-9739-z
4 Shreiner, A.B., Kao, J.Y. and Young, V.B. (2015) The gut microbiome in health and in disease. Curr. Opin. Gastroenterol. 31, 69–75 https://doi.org/10.
1097/MOG.0000000000000139
5 Round, J.L. and Mazmanian, S.K. (2009) The gut microbiota shapes intestinal immune responses during health and disease. Nat. Rev. Immunol. 9,
313–323 https://doi.org/10.1038/nri2515
6 Skardal, A., Shupe, T. and Atala, A. (2016) Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling. Drug Discov.
Today 21, 1399–1411 https://doi.org/10.1016/j.drudis.2016.07.003
7 Esch, E.W., Bahinski, A. and Huh, D. (2015) Organs-on-chips at the frontiers of drug discovery. Nat. Rev. Drug Discov. 14, 248–260 https://doi.org/10.
1038/nrd4539
8 Golovko, D., Kedrin, D., Yilmaz, Ö.H. and Roper, J. (2015) Colorectal cancer models for novel drug discovery. Expert Opin. Drug Discov. 10,
1217–1229 https://doi.org/10.1517/17460441.2015.1079618
© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and the Royal Society of Biology and distributed under the Creative Commons
Attribution License 4.0 (CC BY-NC-ND).
395
Emerging Topics in Life Sciences (2017) 1 385–400
https://doi.org/10.1042/ETLS20170047
9 Vargo-Gogola, T. and Rosen, J.M. (2007) Modelling breast cancer: one size does not ﬁt all. Nat. Rev. Cancer 7, 659–672 https://doi.org/10.1038/
nrc2193
10 van Staveren, W.C.G., Solís, D.Y.W., Hébrant, A., Detours, V., Dumont, J.E. and Maenhaut, C. (2009) Human cancer cell lines: experimental models for
cancer cells in situ? For cancer stem cells? Biochim. Biophys. Acta, Rev. Cancer 1795, 92–103 https://doi.org/10.1016/j.bbcan.2008.12.004
11 Takebe, T., Sekine, K., Enomura, M., Koike, H., Kimura, M., Ogaeri, T. et al. (2013) Vascularized and functional human liver from an iPSC-derived organ
bud transplant. Nature 499, 481–484 https://doi.org/10.1038/nature12271
12 Kim, H.J. and Ingber, D.E. (2013) Gut-on-a-chip microenvironment induces human intestinal cells to undergo villus differentiation. Integr. Biol. 5,
1130–1140 https://doi.org/10.1039/c3ib40126j
13 Artursson, P., Palm, K. and Luthman, K. (2001) Caco-2 monolayers in experimental and theoretical predictions of drug transport1PII of original article:
S0169-409X(96)00415-2. The article was originally published in advanced drug delivery reviews 22 (1996) 67–84.1. Adv. Drug Deliv. Rev. 46, 27–43
https://doi.org/10.1016/S0169-409X(00)00128-9
14 Kim, H.J., Li, H., Collins, J.J. and Ingber, D.E. (2016) Contributions of microbiome and mechanical deformation to intestinal bacterial overgrowth and
inﬂammation in a human gut-on-a-chip. Proc. Natl Acad. Sci. U.S.A. 113, E7–E15 https://doi.org/10.1073/pnas.1522193112
15 Kunz-Schughart, L.A., Freyer, J.P., Hofstaedter, F. and Ebner, R. (2004) The use of 3-D cultures for high-throughput screening: the multicellular
spheroid model. J. Biomol. Screen. 9, 273–285 https://doi.org/10.1177/1087057104265040
16 Ho, W.J., Pham, E.A., Kim, J.W., Ng, C.W., Kim, J.H., Kamei, D.T. et al. (2010) Incorporation of multicellular spheroids into 3-D polymeric scaffolds
provides an improved tumor model for screening anticancer drugs. Cancer Sci. 101, 2637–2643 https://doi.org/10.1111/j.1349-7006.2010.01723.x
17 Drewitz, M., Helbling, M., Fried, N., Bieri, M., Moritz, W., Lichtenberg, J. et al. (2011) Towards automated production and drug sensitivity testing using
scaffold-free spherical tumor microtissues. Biotechnol. J. 6, 1488–1496 https://doi.org/10.1002/biot.201100290
18 Chinwalla, A.T., Cook, L.L., Delehaunty, K.D., Fewell, G.A., Fulton, L.A., Fulton, R.S. et al. (2002) Initial sequencing and comparative analysis of the
mouse genome. Nature 420, 520–562 https://doi.org/10.1038/nature01262
19 Mestas, J. and Hughes, C.C.W. (2004) Of mice and not men: differences between mouse and human immunology. J. Immunol. 172, 2731–2738
https://doi.org/10.4049/jimmunol.172.5.2731
20 Corpet, D.E. and Pierre, F. (2005) How good are rodent models of carcinogenesis in predicting efﬁcacy in humans? A systematic review and
meta-analysis of colon chemoprevention in rats, mice and men. Eur. J. Cancer 41, 1911–1922 https://doi.org/10.1016/j.ejca.2005.06.006
21 Shay, T., Jojic, V., Zuk, O., Rothamel, K., Puyraimond-Zemmour, D., Feng, T. et al. (2013) Conservation and divergence in the transcriptional programs
of the human and mouse immune systems. Proc. Natl Acad. Sci. U.S.A. 110, 2946–2951 https://doi.org/10.1073/pnas.1222738110
22 Frese, K.K. and Tuveson, D.A. (2007) Maximizing mouse cancer models. Nat. Rev. Cancer 7, 654–658 https://doi.org/10.1038/nrc2192
23 Nguyen, T.L.A., Vieira-Silva, S., Liston, A. and Raes, J. (2015) How informative is the mouse for human gut microbiota research? Dis. Models Mech. 8,
1–16 https://doi.org/10.1242/dmm.017400
24 von Martels, J.Z.H., Sadaghian Sadabad, M., Bourgonje, A.R., Blokzijl, T., Dijkstra, G., Faber, K.N. et al. (2017) The role of gut microbiota in health and
disease: in vitro modeling of host-microbe interactions at the aerobe-anaerobe interphase of the human gut. Anaerobe 44, 3–12 https://doi.org/10.
1016/j.anaerobe.2017.01.001
25 Rinke, C., Schwientek, P., Sczyrba, A., Ivanova, N.N., Anderson, I.J., Cheng, J.-F. et al. (2013) Insights into the phylogeny and coding potential of
microbial dark matter. Nature 499, 431–437 https://doi.org/10.1038/nature12352
26 Wilson, I.D. and Nicholson, J.K. (2017) Gut microbiome interactions with drug metabolism, efﬁcacy, and toxicity. Transl. Res. 179, 204–222
https://doi.org/10.1016/j.trsl.2016.08.002
27 Reynolds, B.A. and Weiss, S. (1992) Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science
255, 1707–1710 https://doi.org/10.1126/science.1553558
28 Dontu, G., Abdallah, W.M., Foley, J.M., Jackson, K.W., Clarke, M.F., Kawamura, M.J. et al. (2003) In vitro propagation and transcriptional proﬁling of
human mammary stem/progenitor cells. Genes Dev. 17, 1253–1270 https://doi.org/10.1101/gad.1061803
29 Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J. and Clarke, M.F. (2003) Prospective identiﬁcation of tumorigenic breast cancer cells.
Proc. Natl Acad. Sci. U.S.A. 100, 3983–3988 https://doi.org/10.1073/pnas.0530291100
30 Ponti, D., Costa, A., Zaffaroni, N., Pratesi, G., Petrangolini, G., Coradini, D. et al. (2005) Isolation and in vitro propagation of tumorigenic breast cancer
cells with stem/progenitor cell properties. Cancer Res. 65, 5506–5511 https://doi.org/10.1158/0008-5472.CAN-05-0626
31 Haller, D., Bode, C., Hammes, W.P., Pfeifer, A.M.A., Schiffrin, E.J. and Blum, S. (2000) Non-pathogenic bacteria elicit a differential cytokine response
by intestinal epithelial cell/leucocyte co-cultures. Gut 47, 79–87 https://doi.org/10.1136/gut.47.1.79
32 Gratz, S., Wu, Q.K., El-Nezami, H., Juvonen, R.O., Mykkänen, H. and Turner, P.C. (2007) Lactobacillus rhamnosus strain GG reduces aﬂatoxin B1
transport, metabolism, and toxicity in Caco-2 cells. Appl. Environ. Microbiol. 73, 3958–3964 https://doi.org/10.1128/AEM.02944-06
33 Johnson-Henry, K.C., Donato, K.A., Shen-Tu, G., Gordanpour, M. and Sherman, P.M. (2008) Lactobacillus rhamnosus strain GG prevents
enterohemorrhagic Escherichia coli O157:H7-Induced changes in epithelial barrier function. Infect. Immun. 76, 1340–1348 https://doi.org/10.1128/IAI.
00778-07
34 Roberts, C.L., Keita, Å.V, Duncan, S.H., O’Kennedy, N., Söderholm, J.D., Rhodes, J.M. et al. (2010) Translocation of Crohn’s disease Escherichia coli
across M-cells: contrasting effects of soluble plant ﬁbres and emulsiﬁers. Gut 59, 1331–1339 https://doi.org/10.1136/gut.2009.195370
35 Madsen, K., Cornish, A., Soper, P., McKaigney, C., Jijon, H., Yachimec, C. et al. (2001) Probiotic bacteria enhance murine and human intestinal
epithelial barrier function. Gastroenterology 121, 580–591 https://doi.org/10.1053/gast.2001.27224
36 Mounier, J., Vasselon, T., Hellio, R., Lesourd, M. and Sansonetti, P.J. (1992) Shigella ﬂexneri enters human colonic Caco-2 epithelial cells through the
basolateral pole. Infect. Immun. 60, 237–248 PMID:1729185
37 Roselli, M., Finamore, A., Britti, M.S., Konstantinov, S.R., Smidt, H., de Vos, W.M. et al. (2007) The novel porcine Lactobacillus sobrius strain protects
intestinal cells from enterotoxigenic Escherichia coli K88 infection and prevents membrane barrier damage. J. Nutr. 137, 2709–2716 PMID:18029488
38 Hu, L., Tall, B.D., Curtis, S.K. and Kopecko, D.J. (2008) Enhanced microscopic deﬁnition of Campylobacter jejuni 81-176 adherence to, invasion of,
translocation across, and exocytosis from polarized human intestinal Caco-2 cells. Infect. Immun. 76, 5294–5304 https://doi.org/10.1128/IAI.01408-07
39 Van Deun, K., Pasmans, F., Van Immerseel, F., Ducatelle, R. and Haesebrouck, F. (2008) Butyrate protects Caco-2 cells from Campylobacter jejuni
invasion and translocation. Br. J. Nutr. 100, 480–484 https://doi.org/10.1017/S0007114508921693
© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and the Royal Society of Biology and distributed under the Creative Commons
Attribution License 4.0 (CC BY-NC-ND).
396
Emerging Topics in Life Sciences (2017) 1 385–400
https://doi.org/10.1042/ETLS20170047
40 Rescigno, M., Urbano, M., Valzasina, B., Francolini, M., Rotta, G., Bonasio, R. et al. (2001) Dendritic cells express tight junction proteins and penetrate
gut epithelial monolayers to sample bacteria. Nat. Immunol. 2, 361–367 https://doi.org/10.1038/86373
41 Roselli, M., Finamore, A., Britti, M.S. and Mengheri, E. (2007) Probiotic bacteria Biﬁdobacterium animalis MB5 and Lactobacillus rhamnosus GG protect
intestinal Caco-2 cells from the inﬂammation-associated response induced by enterotoxigenic Escherichia coli K88. Br. J. Nutr. 95, 1177–1184
https://doi.org/10.1079/BJN20051681
42 Noel, G., Baetz, N.W., Staab, J.F., Donowitz, M., Kovbasnjuk, O., Pasetti, M.F. et al. (2017) A primary human macrophage-enteroid co-culture model to
investigate mucosal gut physiology and host-pathogen interactions. Sci. Rep. 7, 45270 https://doi.org/10.1038/srep45270
43 Kim, H.J., Huh, D., Hamilton, G. and Ingber, D.E. (2012) Human gut-on-a-chip inhabited by microbial ﬂora that experiences intestinal peristalsis-like
motions and ﬂow. Lab Chip 12, 2165–2174 https://doi.org/10.1039/c2lc40074j
44 Sato, T., Vries, R.G., Snippert, H.J., van de Wetering, M., Barker, N., Stange, D.E. et al. (2009) Single Lgr5 stem cells build crypt–villus structures
in vitro without a mesenchymal niche. Nature 459, 262–266 https://doi.org/10.1038/nature07935
45 Ootani, A., Li, X., Sangiorgi, E., Ho, Q.T., Ueno, H., Toda, S. et al. (2009) Sustained in vitro intestinal epithelial culture within a Wnt-dependent stem cell
niche. Nat. Med. 15, 701–706 https://doi.org/10.1038/nm.1951
46 Sato, T., Stange, D.E., Ferrante, M., Vries, R.G.J., van Es, J.H., van den Brink, S. et al. (2011) Long-term expansion of epithelial organoids from human
colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology 141, 1762–1772 https://doi.org/10.1053/j.gastro.2011.07.050
47 Parris, A. and Williams, M.R. (2015) A human colonic crypt culture system to study regulation of stem cell-driven tissue renewal and physiological
function. In Stem Cell Renewal and Cell-Cell Communication: Methods and Protocols (Turksen, K., ed.), pp. 141–161, Springer New York, New York, NY
48 Mahe, M.M., Sundaram, N., Watson, C.L., Shroyer, N.F. and Helmrath, M.A. (2015) Establishment of human epithelial enteroids and colonoids from
whole tissue and biopsy. J. Vis. Exp. 97, 52483 https://doi.org/10.3791/52483
49 Hollins, A.J. and Parry, L. (2016) Long-term culture of intestinal cell progenitors: an overview of their development, application, and associated
technologies. Curr. Pathobiol. Rep. 4, 209–219 https://doi.org/10.1007/s40139-016-0119-1
50 Date, S. and Sato, T. (2015) Mini-gut organoids: reconstitution of the stem cell niche. Ann. Rev. Cell Dev. Biol. 31, 269–289 https://doi.org/10.1146/
annurev-cellbio-100814-125218
51 Clevers, H. (2016) Modeling development and disease with organoids. Cell 165, 1586–1597 https://doi.org/10.1016/j.cell.2016.05.082
52 Barker, N., Huch, M., Kujala, P., van de Wetering, M., Snippert, H.J., van Es, J.H. et al. (2010) Lgr5+ve stem cells drive self-renewal in the stomach
and build long-lived gastric units in vitro. Cell Stem Cell 6, 25–36 https://doi.org/10.1016/j.stem.2009.11.013
53 Stange, D.E., Koo, B.-K., Huch, M., Sibbel, G., Basak, O., Lyubimova, A. et al. (2013) Differentiated Troy+ chief cells act as reserve stem cells to
generate all lineages of the stomach epithelium. Cell 155, 357–368 https://doi.org/10.1016/j.cell.2013.09.008
54 Bartfeld, S., Bayram, T., van de Wetering, M., Huch, M., Begthel, H., Kujala, P. et al. (2015) In vitro expansion of human gastric epithelial stem cells
and their responses to bacterial infection. Gastroenterology 148, 126–136.e6 https://doi.org/10.1053/j.gastro.2014.09.042
55 Huch, M., Bonfanti, P., Boj, S.F., Sato, T., Loomans, C.J.M., van de Wetering, M. et al. (2013) Unlimited in vitro expansion of adult bi-potent pancreas
progenitors through the Lgr5/R-spondin axis. EMBO J. 32, 2708–2721 https://doi.org/10.1038/emboj.2013.204
56 Greggio, C., De Franceschi, F., Figueiredo-Larsen, M., Gobaa, S., Ranga, A., Semb, H. et al. (2013) Artiﬁcial three-dimensional niches deconstruct
pancreas development in vitro. Development 140, 4452–4462 https://doi.org/10.1242/dev.096628
57 Boj, S.F., Hwang, C.-I., Baker, L.A., Chio, I.I.C., Engle, D.D., Corbo, V. et al. (2015) Organoid models of human and mouse ductal pancreatic cancer.
Cell 160, 324–338 https://doi.org/10.1016/j.cell.2014.12.021
58 Huch, M., Gehart, H., van Boxtel, R., Hamer, K., Blokzijl, F., Verstegen Monique, M. et al. (2015) Long-Term culture of genome-stable bipotent stem
cells from adult human liver. Cell 160, 299–312 https://doi.org/10.1016/j.cell.2014.11.050
59 Karthaus, W.R., Iaquinta, P.J., Drost, J., Gracanin, A., van Boxtel, R., Wongvipat, J. et al. (2014) Identiﬁcation of multipotent luminal progenitor cells in
human prostate organoid cultures. Cell 159, 163–175 https://doi.org/10.1016/j.cell.2014.08.017
60 Chua, C.W., Shibata, M., Lei, M., Toivanen, R., Barlow, L.J., Bergren, S.K. et al. (2014) Single luminal epithelial progenitors can generate prostate
organoids in culture. Nat. Cell Biol. 16, 951––961 https://doi.org/10.1038/ncb3047
61 DeWard, A.D., Cramer, J. and Lagasse, E. (2014) Cellular heterogeneity in the mouse esophagus implicates the presence of a non-quiescent epithelial
stem cell population. Cell Rep. 9, 701–711 https://doi.org/10.1016/j.celrep.2014.09.027
62 Lugli, N., Kamileri, I., Keogh, A., Malinka, T., Sarris, M.E., Talianidis, I. et al. (2016) R-spondin 1 and noggin facilitate expansion of resident stem cells
from non-damaged gallbladders. EMBO Rep. 17, 769–779 https://doi.org/10.15252/embr.201642169
63 Forbester, J.L., Goulding, D., Vallier, L., Hannan, N., Hale, C., Pickard, D. et al. (2015) Interaction of Salmonella enterica Serovar typhimurium with
intestinal organoids derived from human induced pluripotent stem cells. Infect. Immun. 83, 2926–2934 https://doi.org/10.1128/IAI.00161-15
64 Ren, W., Lewandowski, B.C., Watson, J., Aihara, E., Iwatsuki, K., Bachmanov, A.A. et al. (2014) Single Lgr5- or Lgr6-expressing taste stem/progenitor
cells generate taste bud cells ex vivo. Proc. Natl Acad. Sci. U.S.A. 111, 16401–16406 https://doi.org/10.1073/pnas.1409064111
65 Matano, M., Date, S., Shimokawa, M., Takano, A., Fujii, M., Ohta, Y. et al. (2015) Modeling colorectal cancer using CRISPR-Cas9-mediated engineering
of human intestinal organoids. Nat. Med. 21, 256–262 https://doi.org/10.1038/nm.3802
66 Roper, J., Tammela, T., Cetinbas, N.M., Akkad, A., Roghanian, A., Rickelt, S. et al. (2017) In vivo genome editing and organoid transplantation models
of colorectal cancer and metastasis. Nat. Biotechnol. 35, 569–576 https://doi.org/10.1038/nbt.3836
67 de Sousa e Melo, F., Kurtova, A.V., Harnoss, J.M., Kljavin, N., Hoeck, J.D., Hung, J. et al. (2017) A distinct role for Lgr5+ stem cells in primary and
metastatic colon cancer. Nature 543, 676–680 https://doi.org/10.1038/nature21713
68 McCracken, K.W., Catá, E.M., Crawford, C.M., Sinagoga, K.L., Schumacher, M., Rockich, B.E. et al. (2014) Modeling human development and disease
in pluripotent stem-cell-derived gastric organoids. Nature 516, 400–404 https://doi.org/10.1038/nature13863
69 Schumacher, M.A., Feng, R., Aihara, E., Engevik, A.C., Montrose, M.H., Ottemann, K.M. et al. (2015) Helicobacter pylori-induced sonic hedgehog
expression is regulated by NFκB pathway activation: the use of a novel in vitro model to study epithelial response to infection. Helicobacter 20, 19–28
https://doi.org/10.1111/hel.12152
70 Salama, N.R., Hartung, M.L. and Müller, A. (2013) Life in the human stomach: persistence strategies of the bacterial pathogen Helicobacter pylori.
Nat. Rev. Microbiol. 11, 385–399 https://doi.org/10.1038/nrmicro3016
71 Peek, Jr, R.M., Moss, S.F., Wang, S., Holt, P.R., Tham, K.T., Pérez-Pérez, G.I. et al. (1997) Helicobacter pylori cagA+ strains and dissociation of gastric
epithelial cell proliferation from apoptosis. J. Natl Cancer Inst. 89, 863–868 https://doi.org/10.1093/jnci/89.12.863
© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and the Royal Society of Biology and distributed under the Creative Commons
Attribution License 4.0 (CC BY-NC-ND).
397
Emerging Topics in Life Sciences (2017) 1 385–400
https://doi.org/10.1042/ETLS20170047
72 Churin, Y., Al-Ghoul, L., Kepp, O., Meyer, T.F., Birchmeier, W. and Naumann, M. (2003) Helicobacter pylori CagA protein targets the c-Met receptor and
enhances the motogenic response. J. Cell Biol. 161, 249–255 https://doi.org/10.1083/jcb.200208039
73 Leslie, J.L., Huang, S., Opp, J.S., Nagy, M.S., Kobayashi, M., Young, V.B. et al. (2015) Persistence and toxin production by Clostridium difﬁcile within
human intestinal organoids result in disruption of epithelial paracellular barrier function. Infect. Immun. 83, 138–145 https://doi.org/10.1128/IAI.
02561-14
74 Engevik, M.A., Engevik, K.A., Yacyshyn, M.B., Wang, J., Hassett, D.J., Darien, B. et al. (2015) Human Clostridium difﬁcile infection: inhibition of NHE3
and microbiota proﬁle. Am. J. Physiol. Gastrointest. Liver Physiol. 308, G497–G509 https://doi.org/10.1152/ajpgi.00090.2014
75 Finkbeiner, S.R., Zeng, X.-L., Utama, B., Atmar, R.L., Shroyer, N.F. and Estes, M.K. (2012) Stem cell-derived human intestinal organoids as an infection
model for rotaviruses. mBio 3, e00159-12 https://doi.org/10.1128/mBio.00159-12
76 VanDussen, K.L., Marinshaw, J.M., Shaikh, N., Miyoshi, H., Moon, C., Tarr, P.I. et al. (2015) Development of an enhanced human gastrointestinal
epithelial culture system to facilitate patient-based assays. Gut 64, 911–920 https://doi.org/10.1136/gutjnl-2013-306651
77 In, J., Foulke-Abel, J., Zachos, N.C., Hansen, A.-M., Kaper, J.B., Bernstein, H.D. et al. (2016) Enterohemorrhagic Escherichia coli reduces mucus and
intermicrovillar bridges in human stem cell-derived colonoids. Cell. Mol. Gastroenterol. Hepatol. 2, 48–62.e3 https://doi.org/10.1016/j.jcmgh.2015.10.001
78 Ettayebi, K., Crawford, S.E., Murakami, K., Broughman, J.R., Karandikar, U., Tenge, V.R. et al. (2016) Replication of human noroviruses in stem
cell-derived human enteroids. Science 353, 1387–1393 https://doi.org/10.1126/science.aaf5211
79 Fatehullah, A., Tan, S.H. and Barker, N. (2016) Organoids as an in vitro model of human development and disease. Nat. Cell Biol. 18, 246–254
https://doi.org/10.1038/ncb3312
80 Pocock, K., Delon, L., Bala, V., Rao, S., Priest, C., Prestidge, C. et al. (2017) Intestine-on-a-chip microﬂuidic model for efﬁcient in vitro screening of oral
chemotherapeutic uptake. ACS Biomater. Sci. Eng. 3, 951–959 https://doi.org/10.1021/acsbiomaterials.7b00023
81 Smith, A.M., Prabhakarpandian, B. and Pant, K. (2014) Generation of shear adhesion map using SynVivo synthetic microvascular networks. J. Vis. Exp.
87, 51025 https://doi.org/10.3791/51025
82 Terrell-Hall, T.B., Ammer, A.G., Grifﬁth, J.I.G. and Lockman, P.R. (2017) Permeability across a novel microﬂuidic blood-tumor barrier model. Fluids
Barriers CNS 14, 3 https://doi.org/10.1186/s12987-017-0050-9
83 Deosarkar, S.P., Prabhakarpandian, B., Wang, B., Shefﬁeld, J.B., Krynska, B. and Kiani, M.F. (2015) A novel dynamic neonatal blood-brain barrier on a
chip. PLoS ONE 10, e0142725 https://doi.org/10.1371/journal.pone.0142725
84 Prabhakarpandian, B., Shen, M.-C., Nichols, J.B., Mills, I.R., Sidoryk-Wegrzynowicz, M., Aschner, M. et al. (2013) SyM-BBB: a microﬂuidic blood brain
barrier model. Lab Chip 13, 1093–1101 https://doi.org/10.1039/c2lc41208j
85 Prabhakarpandian, B., Shen, M.-C., Nichols, J.B., Garson, C.J., Mills, I.R., Matar, M.M. et al. (2015) Synthetic tumor networks for screening drug
delivery systems. J. Control. Release 201, 49–55 https://doi.org/10.1016/j.jconrel.2015.01.018
86 Lamberti, G., Prabhakarpandian, B., Garson, C., Smith, A., Pant, K., Wang, B. et al. (2014) Bioinspired microﬂuidic assay for in vitro modeling of
leukocyte–endothelium interactions. Anal. Chem. 86, 8344–8351 https://doi.org/10.1021/ac5018716
87 Soroush, F., Zhang, T., King, D.J., Tang, Y., Deosarkar, S., Prabhakarpandian, B. et al. (2016) A novel microﬂuidic assay reveals a key role for protein
kinase C δ in regulating human neutrophil-endothelium interaction. J. Leukoc. Biol. 100, 1027–1035 https://doi.org/10.1189/jlb.3MA0216-087R
88 van de Bovenkamp, M., Groothuis, G.M.M., Draaisma, A.L., Merema, M.T., Bezuijen, J.I., van Gils, M.J. et al. (2005) Precision-cut liver slices as a new
model to study toxicity-induced hepatic stellate cell activation in a physiologic milieu. Toxicol. Sci. 85, 632–638 https://doi.org/10.1093/toxsci/kﬁ127
89 Martignoni, M., Groothuis, G. and de Kanter, R. (2006) Comparison of mouse and rat cytochrome P450-mediated metabolism in liver and intestine.
Drug Metab. Dispos. 34, 1047–1054 https://doi.org/10.1124/dmd.105.009035
90 Groothuis, G.M.M. and de Graaf, I.A.M. (2013) Precision-cut intestinal slices as in vitro tool for studies on drug metabolism. Curr. Drug Metab. 14,
112–119 https://doi.org/10.2174/138920013804545197
91 Li, M., de Graaf, I.A.M. and Groothuis, G.M.M. (2016) Precision-cut intestinal slices: alternative model for drug transport, metabolism, and toxicology
research. Expert Opin. Drug Metab. Toxicol. 12, 175–190 https://doi.org/10.1517/17425255.2016.1125882
92 de Graaf, I.A.M., Olinga, P., de Jager, M.H., Merema, M.T., de Kanter, R., van de Kerkhof, E.G. et al. (2010) Preparation and incubation of precision-cut
liver and intestinal slices for application in drug metabolism and toxicity studies. Nat. Protoc. 5, 1540–1551 https://doi.org/10.1038/nprot.2010.111
93 Schwerdtfeger, L.A., Ryan, E.P. and Tobet, S.A. (2016) An organotypic slice model for ex vivo study of neural, immune, and microbial interactions of
mouse intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 310, G240–G248 https://doi.org/10.1152/ajpgi.00299.2015
94 Maier, E., Anderson, R.C. and Roy, N.C. (2015) Understanding how commensal obligate anaerobic bacteria regulate immune functions in the large
intestine. Nutrients 7, 45–73 https://doi.org/10.3390/nu7010045
95 Clarke, L.L. (2009) A guide to Ussing chamber studies of mouse intestine. Am. J. Physiol. Gastrointest. Liver Physiol. 296, G1151–G1166
https://doi.org/10.1152/ajpgi.90649.2008
96 Forner, K., Roos, C., Dahlgren, D., Kesisoglou, F., Konerding, M.A., Mazur, J. et al. (2017) Optimization of the Ussing chamber setup with excised rat
intestinal segments for dissolution/permeation experiments of poorly soluble drugs. Drug Dev. Ind. Pharm. 43, 338–346 https://doi.org/10.1080/
03639045.2016.1251449
97 Rozehnal, V., Nakai, D., Hoepner, U., Fischer, T., Kamiyama, E., Takahashi, M. et al. (2012) Human small intestinal and colonic tissue mounted in the
Ussing chamber as a tool for characterizing the intestinal absorption of drugs. Eur. J. Pharm. Sci. 46, 367–373 https://doi.org/10.1016/j.ejps.2012.02.025
98 Gustafsson, J.K., Navabi, N., Rodriguez-Piñeiro, A.M., Alomran, A.H.A., Premaratne, P., Fernandez, H.R. et al. (2013) Dynamic changes in mucus
thickness and ion secretion during Citrobacter rodentium infection and clearance. PLoS ONE 8, e84430 https://doi.org/10.1371/journal.pone.0084430
99 Llopis, M., Antolin, M., Carol, M., Borruel, N., Casellas, F., Martinez, C. et al. (2009) Lactobacillus casei downregulates commensals’ inﬂammatory
signals in Crohn’s disease mucosa. Inﬂamm. Bowel Dis. 15, 275–283 https://doi.org/10.1002/ibd.20736
100 Parassol, N., Freitas, M., Thoreux, K., Dalmasso, G., Bourdet-Sicard, R. and Rampal, P. (2005) Lactobacillus casei DN-114 001 inhibits the increase in
paracellular permeability of enteropathogenic Escherichia coli-infected T84 cells. Res. Microbiol. 156, 256–262 https://doi.org/10.1016/j.resmic.2004.
09.013
101 Jafari, N.V., Kuehne, S.A., Minton, N.P., Allan, E. and Bajaj-Elliott, M. (2016) Clostridium difﬁcile-mediated effects on human intestinal epithelia:
modelling host-pathogen interactions in a vertical diffusion chamber. Anaerobe 37, 96–102 https://doi.org/10.1016/j.anaerobe.2015.12.007
102 Anabazhagan, A.N., Chatterjee, I., Priyamvada, S., Kumar, A., Tyagi, S., Saksena, S. et al. (2017) Methods to study epithelial transport protein function
and expression in native intestine and Caco-2 cells grown in 3D. J. Vis. Exp. 121, e55304 https://doi.org/10.3791/55304
© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and the Royal Society of Biology and distributed under the Creative Commons
Attribution License 4.0 (CC BY-NC-ND).
398
Emerging Topics in Life Sciences (2017) 1 385–400
https://doi.org/10.1042/ETLS20170047
103 Jespersen, B., Tykocki, N.R., Watts, S.W. and Cobbett, P.J. (2015) Measurement of smooth muscle function in the isolated tissue bath-applications to
pharmacology research. J. Vis. Exp. 95, 52324 https://doi.org/10.3791/52324
104 Fry, C.H. (2004) Experimental models to study the physiology, pathophysiology, and pharmacology of the lower urinary tract. J. Pharmacol. Toxicol.
Methods 49, 201–210 https://doi.org/10.1016/j.vascn.2004.03.002
105 Chan, W.W. and Mashimo, H. (2013) Lubiprostone increases small intestinal smooth muscle contractions through a prostaglandin E receptor 1
(EP1)-mediated pathway. J. Neurogastroenterol. Motil. 19, 312–318 https://doi.org/10.5056/jnm.2013.19.3.312
106 Villa, L., Buono, R., Fossati, N., Rigatti, P., Montorsi, F., Benigni, F. et al. (2013) Effects by silodosin on the partially obstructed rat ureter in vivo and on
human and rat isolated ureters. Br. J. Pharmacol. 169, 230–238 https://doi.org/10.1111/bph.12123
107 Bär, F., Von Koschitzky, H., Roblick, U., Bruch, H.P., Schulze, L., Sonnenborn, U. et al. (2009) Cell-free supernatants of Escherichia coli Nissle 1917
modulate human colonic motility: evidence from an in vitro organ bath study. Neurogastroenterol. Motil. 21, 559-e17 https://doi.org/10.1111/j.
1365-2982.2008.01258.x
108 Yum, K., Hong, S.G., Healy, K.E. and Lee, L.P. (2014) Physiologically relevant organs on chips. Biotechnol. J. 9, 16–27 https://doi.org/10.1002/biot.
201300187
109 Hu, Y., Bian, S., Grotberg, J., Filoche, M., White, J., Takayama, S. et al. (2015) A microﬂuidic model to study ﬂuid dynamics of mucus plug rupture in
small lung airways. Biomicroﬂuidics 9, 044119 https://doi.org/10.1063/1.4928766
110 An, F., Qu, Y., Liu, X., Zhong, R. and Luo, Y. (2015) Organ-on-a-chip: new platform for biological analysis. Anal. Chem. Insights 10, 39–45
https://doi.org/10.4137/ACI.S28905
111 Huh, D., Matthews, B.D., Mammoto, A., Montoya-Zavala, M., Hsin, H.Y. and Ingber, D.E. (2010) Reconstituting organ-level lung functions on a chip.
Science 328, 1662–1668 https://doi.org/10.1126/science.1188302
112 Huh, D., Leslie, D.C., Matthews, B.D., Fraser, J.P., Jurek, S., Hamilton, G.A. et al. (2012) A human disease model of drug toxicity-Induced pulmonary
edema in a lung-on-a-chip microdevice. Sci. Transl. Med. 4, 159ra147 https://doi.org/10.1126/scitranslmed.3004249
113 Nguyen, M.-D., Tinney, J.P., Ye, F., Elnakib, A.A., Yuan, F., El-Baz, A. et al. (2015) Effects of physiologic mechanical stimulation on embryonic chick
cardiomyocytes using a microﬂuidic cardiac cell culture model. Anal. Chem. 87, 2107–2113 https://doi.org/10.1021/ac503716z
114 Chen, H., Cornwell, J., Zhang, H., Lim, T., Resurreccion, R., Port, T. et al. (2013) Cardiac-like ﬂow generator for long-term imaging of endothelial cell
responses to circulatory pulsatile ﬂow at microscale. Lab Chip 13, 2999–3007 https://doi.org/10.1039/c3lc50123j
115 Bhise, N.S., Manoharan, V., Massa, S., Tamayol, A., Ghaderi, M., Miscuglio, M. et al. (2016) A liver-on-a-chip platform with bioprinted hepatic
spheroids. Biofabrication 8, 014101 https://doi.org/10.1088/1758-5090/8/1/014101
116 Shamloo, A., Heibatollahi, M. and Mofrad, M.R.K. (2015) Directional migration and differentiation of neural stem cells within three-dimensional
microenvironments. Integr. Biol. 7, 335–344 https://doi.org/10.1039/C4IB00144C
117 Jang, K. and Suh, K. (2010) A multi-layer microﬂuidic device for efﬁcient culture and analysis of renal tubular cells. Lab Chip 10, 36–42
https://doi.org/10.1039/b907515a
118 Jang, K.-J., Mehr, A.P., Hamilton, G.A., McPartlin, L.A., Chung, S., Suh, K.-Y. et al. (2013) Human kidney proximal tubule-on-a-chip for drug transport
and nephrotoxicity assessment. Integr. Biol. 5, 1119–1129 https://doi.org/10.1039/c3ib40049b
119 Kimura, H., Yamamoto, T., Sakai, H., Sakai, Y. and Fujii, T. (2008) An integrated microﬂuidic system for long-term perfusion culture and on-line
monitoring of intestinal tissue models. Lab Chip 8, 741–746 https://doi.org/10.1039/b717091b
120 Tsai, M., Kita, A., Leach, J., Rounsevell, R., Huang, J.N., Moake, J. et al. (2012) In vitro modeling of the microvascular occlusion and thrombosis that
occur in hematologic diseases using microﬂuidic technology. J. Clin. Invest. 122, 408–418 https://doi.org/10.1172/JCI58753
121 Theberge, A.B., Yu, J., Young, E.W.K., Ricke, W.A., Bushman, W. and Beebe, D.J. (2015) Microﬂuidic multiculture assay to analyze biomolecular
signaling in angiogenesis. Anal. Chem. 87, 3239–3246 https://doi.org/10.1021/ac503700f
122 Walsh, C.L., Babin, B.M., Kasinskas, R.W., Foster, J.A., McGarry, M.J. and Forbes, N.S. (2009) A multipurpose microﬂuidic device designed to mimic
microenvironment gradients and develop targeted cancer therapeutics. Lab Chip 9, 545–554 https://doi.org/10.1039/b810571e
123 Torisawa, Y.-s., Spina, C.S., Mammoto, T., Mammoto, A., Weaver, J.C., Tat, T. et al. (2014) Bone marrow–on–a–chip replicates hematopoietic niche
physiology in vitro. Nat. Methods 11, 663–669 https://doi.org/10.1038/nmeth.2938
124 Sung, J.H., Kam, C. and Shuler, M. (2010) A microﬂuidic device for a pharmacokinetic–pharmacodynamic (PK–PD) model on a chip. Lab Chip 10, 446
https://doi.org/10.1039/b917763a
125 Maschmeyer, I., Lorenz, A., Ramme, A., Hasenberg, T., Schimek, K., Hübner, J. et al. (2015) A microﬂuidic four-organ-chip for interconnected
long-term co-culture of human intestine, liver, skin and kidney equivalents. Toxicol. Lett. 238, 176 https://doi.org/10.1016/j.toxlet.2015.08.512
126 Vernetti, L., Gough, A., Baetz, N., Blutt, S., Broughman, J.R., Brown, J.A. et al. (2017) Functional coupling of human microphysiology systems: intestine,
liver, kidney proximal tubule, blood-brain barrier and skeletal muscle. Sci. Rep. 7, 42296 https://doi.org/10.1038/srep42296
127 Imura, Y., Asano, Y., Sato, K. and Yoshimura, E. (2009) A microﬂuidic system to evaluate intestinal absorption. Anal. Sci. 25, 1403–1407 https://doi.
org/10.2116/analsci.25.1403
128 Dai, C., Zhao, D.-H. and Jiang, M. (2012) VSL#3 probiotics regulate the intestinal epithelial barrier in vivo and in vitro via the p38 and ERK signaling
pathways. Int. J. Mol. Med. 29, 202–208 https://doi.org/10.3892/ijmm.2011.839
129 Chapman, T.M., Plosker, G.L. and Figgitt, D.P. (2007) Spotlight on VSL#3 probiotic mixture in chronic inﬂammatory bowel diseases. BioDrugs 21,
61–63 https://doi.org/10.2165/00063030-200721010-00007
130 Sbrana, T. and Ahluwalia, A. (2012) Engineering quasi-vivo in vitro organ models. Adv. Exp. Med. Biol. 745, 138–153 https://doi.org/10.1007/
978-1-4614-3055-1_9
131 Lindstedt, S.L. and Schaeffer, P.J. (2002) Use of allometry in predicting anatomical and physiological parameters of mammals. Lab. Anim. 36, 1–19
https://doi.org/10.1258/0023677021911731
132 Ahluwalia, A. (2017) Allometric scaling in-vitro. Sci. Rep. 7, 42113 https://doi.org/10.1038/srep42113
133 Nithiananthan, S., Crawford, A., Knock, J.C., Lambert, D.W. and Whawell, S.A. (2017) Physiological ﬂuid ﬂow moderates ﬁbroblast responses to
TGF-β1. J. Cell. Biochem. 118, 878–890 https://doi.org/10.1002/jcb.25767
134 Shah, P., Fritz, J.V., Glaab, E., Desai, M.S., Greenhalgh, K., Frachet, A. et al. (2016) A microﬂuidics-based in vitro model of the gastrointestinal
human-microbe interface. Nat. Commun. 7, 11535 https://doi.org/10.1038/ncomms11535
© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and the Royal Society of Biology and distributed under the Creative Commons
Attribution License 4.0 (CC BY-NC-ND).
399
Emerging Topics in Life Sciences (2017) 1 385–400
https://doi.org/10.1042/ETLS20170047
135 Eain, M.M.G., Baginska, J., Greenhalgh, K., Fritz, J.V., Zenhausern, F. and Wilmes, P. (2017) Engineering solutions for representative models of the
gastrointestinal human-microbe interface. Engineering 3, 60–65 https://doi.org/10.1016/J.ENG.2017.01.011
136 Donaldson, G.P., Lee, S.M. and Mazmanian, S.K. (2016) Gut biogeography of the bacterial microbiota. Nat. Rev. Microbiol. 14, 20–32 https://doi.org/
10.1038/nrmicro3552
137 Atuma, C., Strugala, V., Allen, A. and Holm, L. (2001) The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo.
Am. J. Physiol. Gastrointest. Liver Physiol. 280, G922–G929 PMID:11292601
138 van der Meer, A.D. and van den Berg, A. (2012) Organs-on-chips: breaking the in vitro impasse. Integr. Biol. 4, 461–470 https://doi.org/10.1039/
c2ib00176d
139 Berthier, E., Young, E.W.K. and Beebe, D. (2012) Engineers are from PDMS-land, biologists are from Polystyrenia. Lab Chip 12, 1224–1237 https://doi.
org/10.1039/c2lc20982a
140 Wong, I. and Ho, C.-M. (2009) Surface molecular property modiﬁcations for poly(dimethylsiloxane) (PDMS) based microﬂuidic devices. Microﬂuidics
Nanoﬂuidics 7, 291–306 https://doi.org/10.1007/s10404-009-0443-4
141 Domansky, K., Leslie, D.C., McKinney, J., Fraser, J.P., Sliz, J.D., Hamkins-Indik, T. et al. (2013) Clear castable polyurethane elastomer for fabrication of
microﬂuidic devices. Lab Chip 13, 3956–3964 https://doi.org/10.1039/c3lc50558h
142 van Midwoud, P.M., Janse, A., Merema, M.T., Groothuis, G.M.M. and Verpoorte, E. (2012) Comparison of biocompatibility and adsorption properties of
different plastics for advanced microﬂuidic cell and tissue culture models. Anal. Chem. 84, 3938–3944 https://doi.org/10.1021/ac300771z
143 Esch, M.B., Mahler, G.J., Stokol, T. and Shuler, M.L. (2014) Body-on-a-chip simulation with gastrointestinal tract and liver tissues suggests that
ingested nanoparticles have the potential to cause liver injury. Lab Chip 14, 3081–3092 https://doi.org/10.1039/C4LC00371C
144 Perestrelo, A.R., Águas, A.C.P., Rainer, A. and Forte, G. (2015) Microﬂuidic organ/body-on-a-chip devices at the convergence of biology and
microengineering. Sensors 15, 31142–31170 https://doi.org/10.3390/s151229848
145 Justus, C.R., Lefﬂer, N., Ruiz-Echevarria, M. and Yang, L.V. (2014) In vitro cell migration and invasion assays. J. Vis. Exp. 88, 51046 https://doi.org/10.
3791/51046
146 Castellone, R.D., Lefﬂer, N.R., Dong, L. and Yang, L.V. (2011) Inhibition of tumor cell migration and metastasis by the proton-sensing GPR4 receptor.
Cancer Lett. 312, 197–208 https://doi.org/10.1016/j.canlet.2011.08.013
147 Man, S., Ubogu, E.E., Williams, K.A., Tucky, B., Callahan, M.K. and Ransohoff, R.M. (2008) Human brain microvascular endothelial cells and umbilical
vein endothelial cells differentially facilitate leukocyte recruitment and utilize chemokines for T cell migration. Clin. Dev. Immunol. 2008, 384982
https://doi.org/10.1155/2008/384982
148 Antoni, D., Burckel, H., Josset, E. and Noel, G. (2015) Three-dimensional cell culture: a breakthrough in vivo. Int. J. Mol. Sci. 16, 5517–5527
https://doi.org/10.3390/ijms16035517
149 Edmondson, R., Broglie, J.J., Adcock, A.F. and Yang, L. (2014) Three-dimensional cell culture systems and their applications in drug discovery and
cell-based biosensors. Assay Drug Dev. Technol. 12, 207–218 https://doi.org/10.1089/adt.2014.573
150 Cox, M.C., Reese, L.M., Bickford, L.R. and Verbridge, S.S. (2015) Toward the broad adoption of 3D tumor models in the cancer drug pipeline. ACS
Biomater. Sci. Eng. 1, 877–894 https://doi.org/10.1021/acsbiomaterials.5b00172
151 Hill, D.R. and Spence, J.R. (2017) Gastrointestinal organoids: understanding the molecular basis of the host–microbe interface. Cell. Mol. Gastroenterol.
Hepatol. 3, 138–149 https://doi.org/10.1016/j.jcmgh.2016.11.007
152 Grivel, J.-C. and Margolis, L. (2009) Use of human tissue explants to study human infectious agents. Nat. Protoc. 4, 256–269 https://doi.org/10.1038/
nprot.2008.245
153 Kim, S. and Takayama, S. (2015) Organ-on-a-chip and the kidney. Kidney Res. Clin. Pract. 34, 165–169 https://doi.org/10.1016/j.krcp.2015.08.001
154 Aziz, U.A., Geng, C., Fu, M., Yu, X., Qin, K. and Liu, B. (2017) The role of microﬂuidics for organ on chip simulations. Bioengineering 4, E39 https://doi.
org/10.3390/bioengineering4020039
155 Valencia, P.M., Farokhzad, O.C., Karnik, R. and Langer, R. (2012) Microﬂuidic technologies for accelerating the clinical translation of nanoparticles.
Nat. Nanotechnol. 7, 623–629 https://doi.org/10.1038/nnano.2012.168
156 Bhatia, S.N. and Ingber, D.E. (2014) Microﬂuidic organs-on-chips. Nat. Biotechnol. 32, 760–772 https://doi.org/10.1038/nbt.2989
157 Pagliari, S., Tirella, A., Ahluwalia, A., Duim, S., Goumans, M.-J., Aoyagi, T. et al. (2014) A multistep procedure to prepare pre-vascularized cardiac
tissue constructs using adult stem cells, dynamic cell cultures, and porous scaffolds. Front. Physiol. 5, 210 https://doi.org/10.3389/fphys.2014.00210
158 Mazzei, D., Guzzardi, M.A., Giusti, S. and Ahluwalia, A. (2010) A low shear stress modular bioreactor for connected cell culture under high ﬂow rates.
Biotechnol. Bioeng. 106, 127–137 https://doi.org/10.1002/bit.22671
© 2017 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and the Royal Society of Biology and distributed under the Creative Commons
Attribution License 4.0 (CC BY-NC-ND).
400
Emerging Topics in Life Sciences (2017) 1 385–400
https://doi.org/10.1042/ETLS20170047
